Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma

References

• Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–12. doi:10.1182/BLOOD-2017-03-769620.
   PubMed Web of Science ®Google Scholar
• Hagberg H, Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol. 2006;17(SUPPL. 4):iv31–iv32. doi:10.1093/ANNONC/MDJ996.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-Cell lymphoma. J Clin Oncol. 2020;38(2):155–165. doi:10.1200/JCO.19.00172.
   PubMed Web of Science ®Google Scholar
• Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–988. doi:10.1016/S1470-2045(20)30225-4.
   PubMed Web of Science ®Google Scholar
• Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790–800. doi:10.1016/S1470-2045(21)00139-X.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi:10.1056/nejmoa1707447.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45–56. doi:10.1056/nejmoa1804980.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852. doi:10.1016/S0140-6736(20)31366-0.
   PubMed Web of Science ®Google Scholar
• Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, et al. Axicabtagene ciloleucel as second-line therapy for large B-Cell Lymphoma. N Engl J Med. 2022;386(7):640–654. doi:10.1056/NEJMoa2116133.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 transform study. Blood. 2023;141(14):1675–1684. doi:10.1182/blood.2022018730.
   PubMed Web of Science ®Google Scholar
• Petrazzuolo A, Maiuri MC, Zitvogel L, Kroemer G, Kepp O. Trial watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. Oncoimmunology. 2022;11(1). doi: 10.1080/2162402X.2022.2077898.
   PubMed Web of Science ®Google Scholar
• Le Naour J, Kroemer G. Trial watch: toll-like receptor ligands in cancer therapy. Oncoimmunology. 2023;12(1). doi: 10.1080/2162402X.2023.2180237.
   Web of Science ®Google Scholar
• Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, Govaerts J, Naulaerts S, Berneman ZN, Beuselinck B, Bol KF, Borst J, et al. Trial watch: dendritic cell (DC)-based immunotherapy for cancer. Oncoimmunology. 2022;11(1). doi:10.1080/2162402X.2022.2096363.
   PubMed Web of Science ®Google Scholar
• Sprooten J, Laureano RS, Vanmeerbeek I, Govaerts J, Naulaerts S, Borras DM, Kinget L, Fucíková J, Špíšek R, Jelínková LP, et al. Trial watch: chemotherapy-induced immunogenic cell death in oncology. Oncoimmunology. 2023;12(1). doi:10.1080/2162402X.2023.2219591.
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20(7):838–847. doi:10.1016/J.DRUDIS.2015.02.008.
   PubMed Web of Science ®Google Scholar
• Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E. et al, Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015;7(287). doi:10.1126/scitranslmed.aaa4802.
   Web of Science ®Google Scholar
• Atwell S, Ridgway JBB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol. 1997;270(1):26–35. doi:10.1006/JMBI.1997.1116.
   PubMed Web of Science ®Google Scholar
• Klein C, Schaefer W, Regula JT. The use of CrossMAb technology for the generation of bi- and multispecific antibodies. MAbs. 2016;8(6):1010–1020. doi:10.1080/19420862.2016.1197457.
   PubMed Web of Science ®Google Scholar
• Challa-Malladi M, Lieu YK, Califano O, Holmes AB, Bhagat G, Murty VV, Dominguez-Sola D, Pasqualucci L, Dalla-Favera R. Combined genetic inactivation of β2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011;20(6):728–740. doi:10.1016/J.CCR.2011.11.006.
   PubMed Web of Science ®Google Scholar
• Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(26):4024–4031. doi:10.1182/BLOOD-2014-12-614636.
   PubMed Web of Science ®Google Scholar
• Wei J, Montalvo-Ortiz W, Yu L, Krasco A, Olson K, Rizvi S, Fiaschi N, Coetzee S, Wang F, Ullman E, et al. CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models. Sci Transl Med. 2022;14(670). doi:10.1126/scitranslmed.abn1082.
   Web of Science ®Google Scholar
• Wang J, Li C, He K, Kuang Z, Lu J, Yao Y, He F, Li N, Li L, Fu F, et al. Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies. Cancer Immunol Immunother. 2023;72(2):493–507. doi:10.1007/s00262-022-03267-5.
   PubMed Web of Science ®Google Scholar
• Buatois V, Johnson Z, Salgado-Pires S, Papaioannou A, Hatterer E, Chauchet X, Richard F, Barba L, Daubeuf B, Cons L, et al. Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B-cell lymphoma and leukemia. Mol Cancer Ther. 2018;17(8):1739–1751. doi:10.1158/1535-7163.MCT-17-1095.
   PubMed Web of Science ®Google Scholar
• Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018;24(19):4785–4797. doi:10.1158/1078-0432.CCR-18-0455.
   PubMed Web of Science ®Google Scholar
• Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Beltran Hernandez I, Oostindie SC, Neijssen J, van den Brink EN, Horbach GJ, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625. doi:10.1016/j.ebiom.2019.102625.
   PubMed Web of Science ®Google Scholar
• Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, Oyejide A, Kirshner JR, Canova L, Menon J, et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep. 2015;5(1):1–12. doi:10.1038/srep17943.
   Google Scholar
• Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-Cell-engaging antibody, in relapsed or refractory large B-Cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2023;41(12):2238–2247. doi:10.1200/JCO.22.01725.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martinez-Lopez J, Crump M, Thomas DN, et al. Glofitamab, a novel, bivalent CD20-targeting T-Cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-Cell lymphoma: a phase I trial. J Clin Oncol. 2021;39(18):1959–1970. doi:10.1200/JCO.20.03175.
   PubMed Web of Science ®Google Scholar
• Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon S-S, Hyun Yoon D, Matasar MJ, Bosch F, Seog Kim W, Nastoupil LJ, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-Cell Lymphomas: phase I dose-escalation study. J Clin Oncol. 2021;40(5):481–491. doi:10.1200/JCO.21.
   PubMed Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638. doi:10.1016/J.BBMT.2018.12.758.
   PubMed Web of Science ®Google Scholar
• Gust J, Finney OC, Li D, Brakke HM, Hicks RM, Futrell RB, Gamble DN, Rawlings-Rhea SD, Khalatbari HK, Ishak GE, et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019;86(1):42–54. doi:10.1002/ANA.25502.
   PubMed Web of Science ®Google Scholar
• Hosseini I, Gadkar K, Stefanich E, Li CC, Sun LL, Chu YW, Ramanujan S. Mitigating the risk of cytokine release syndrome in a phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020;6(1):1–11. doi:10.1038/s41540-020-00145-7.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Giri P, Budde LE, Schuster SJ, Assouline S, Matasar MJ, Yoon S-S, Canales M, Gutierrez NC, Fay K, et al. Subcutaneous (SC) administration of mosunetuzumab with cycle 1 step-up dosing is tolerable and active in patients with relapsed/refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): initial results from a phase I/II study. Blood. 2021;138(Supplement 1):3573–3573. doi:10.1182/BLOOD-2021-147937.
   Google Scholar
• Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O’Brien SM, Chávez JC, Duell J, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9(5):e327–e339. doi:10.1016/S2352-3026(22)00072-2.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, Lewis DJ, Sureda Balari A, Cunningham D, Oliveri RS, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021;398(10306):1157–1169. doi:10.1016/S0140-6736(21)00889-8.
   PubMed Web of Science ®Google Scholar
• Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023;141(5):467–480. doi:10.1182/blood.2021011994.
   PubMed Web of Science ®Google Scholar
• Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wróbel T, Offner F, Trněný M, et al. Glofitamab for relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2022;387(24):2220–2231. doi:10.1056/NEJMoa2206913.
   PubMed Web of Science ®Google Scholar
• Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil LJ, Thieblemont C, Ursu R, Bartlett NL, Nachar VR, et al. Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy. Blood J. 2024 Jan 22. doi:10.1182/BLOOD.2023022432.
   Google Scholar
• Viardot A, Goebeler M-E, Hess G, Neumann S, Pfreundschuh M, Adrian N, Zettl F, Libicher M, Sayehli C, Stieglmaier J, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410–1416. doi:10.1182/blood-2015-06.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CYY, Matasar MJ, Gregory GP, Yoon D-H, Shadman M, Fay K, et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2023;7(17):4926–4935. doi:10.1182/BLOODADVANCES.2022009260.
   PubMed Web of Science ®Google Scholar
• EPKINLYTM for 3L+ large B-cell lymphoma - official HCP site. [accessed 2023 Dec 25]. https://www.epkinlyhcp.com/.
   Google Scholar
• Genentech: ColumviTM (glofitamab-gxbm) - information for patients. [accessed 2023 Dec 26]. https://www.gene.com/patients/medicines/columvi.
   Google Scholar
• Hutchings M, Carlo-Stella C, Morschhauser F, Falchi L, Bachy E, Cartron G, Khan C, Tani M, Martinez-Lopez J, Bartlett NL, et al. Glofitamab monotherapy in relapsed or refractory large B-Cell lymphoma: extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-Cell therapy and by baseline total metabolic tumor volume. Blood. 2023;142(Supplement 1):433–433. doi:10.1182/BLOOD-2023-173951.
   Google Scholar
• Song Y-Q, Zhang H-L, Huang H-Q, Zhang Q-Y, Jing H-M, Wang C, Wu C, Li D-H, Dai Y, Humphrey K, et al. Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2023 Oct 19. doi:10.3324/HAEMATOL.2023.283802.
   Google Scholar
• Crombie JL, Matasar M, Topp MS, Allan JN, Barnes JA, Arnason JE, Michot J-M, Goldschmidt N, O’Brien SM, Abadi U, et al. Odronextamab demonstrates durable complete responses in patients with diffuse large B-Cell lymphoma (DLBCL) progressing after CAR-T therapy: outcomes from the ELM-1 study. Blood. 2023;142(Supplement 1):4461–4461. doi:10.1182/BLOOD-2023-181602.
   Google Scholar
• Ayyappan S, Kim WS, Kim TM, Walewski J, Cho S-G, Jarque I, Iskierka-Jazdzewska E, Poon M, Oh SY, Inng Lim FLW, et al. Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed/refractory (R/R) diffuse large B-Cell lymphoma (DLBCL). Blood. 2023;142(Supplement 1):436–436. doi:10.1182/BLOOD-2023-179818.
   Google Scholar
• Patel K, Riedell PA, Tilly H, Ahmed S, Michot J-M, Ghesquieres H, Schiano de Collela JM, Chanan-Khan A, Bouabdallah K, Tessoulin B, et al. A phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with Relapsed/Refractory Non-Hodgkin’s lymphoma: recommended dose Safety/Efficacy update and escalation exposure-response analysis. Blood. 2022;140(Supplement 1):9470–9472. doi:10.1182/BLOOD-2022-159586.
   Google Scholar
• Budde E, Gopal AK, Kim WS, Flinn IW, Cheah CYY, Nastoupil L, Matasar MJ, Diefenbach CS, Gregory GP, Qazi I, et al. A phase 1 dose escalation study of igm-2323, a novel anti-CD20 x anti-CD3 IgM T cell engager (TCE) in patients with advanced B-Cell malignancies. Blood. 2021;138(Supplement 1):132–132. doi:10.1182/BLOOD-2021-153355.
   Google Scholar
• Li C-C, Bender B, Yin S, Li Z, Zhang C, Hernandez G, Kwan A, Sun L, Adamkewicz JI, Wang H, et al. Exposure-response analyses indicate a promising benefit/risk profile of mosunetuzumab in relapsed and refractory Non-Hodgkin Lymphoma. Blood. 2019;134(Supplement_1):1285. doi:10.1182/BLOOD-2019-123961.
   Google Scholar
• Chiu CW, Hiemstra IH, ten HW, Snijdewint-Nkairi R, de JB, Castro PG, Kweekel C, Oliveri RS, Elliot B, Wielgos-Bonvallet M, et al. Preclinical evaluation of epcoritamab combined with standard of care agents for the treatment of B-cell lymphomas. Hematol Oncol. 2021;39(S2). doi:10.1002/HON.78_2881.
   Google Scholar
• Abrisqueta P, Falchi L, Phillips TJ, De Vos S, Nijland M, Offner F, Bykhovski I, Wu J, Wang L, Rana A, et al. Subcutaneous epcoritamab + R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT): preliminary phase 1/2 results. J Clin Oncol. 2022;40(16_suppl):7528–7528. doi:10.1200/JCO.2022.40.16_SUPPL.7528.
   Web of Science ®Google Scholar
• Brody J, Joergensen JM, Belada D, Costello RT, Trněný M, Vitolo U, Lewis D, Karimi YH, Sureda Balari AM, André M, et al. Epcoritamab SC + GemOx leads to high complete metabolic response rates in patients with Relapsed/Refractory diffuse large B-Cell lymphoma ineligible for autologous stem cell transplant: updated results from Epcore NHL-2. Blood. 2023;142(Supplement 1):3092–3092. doi:10.1182/BLOOD-2023-180246.
   Google Scholar
• Budde LE, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Kamdar M, Ghosh N, Modi D, Sabry W, Naik S, et al. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. Nat Med. 2023 Dec;10(1):229–239. doi:10.1038/s41591-023-02726-5.
   Google Scholar
• Hutchings M, Avigdor A, Sureda Balari AM, Terol MJ, Bosch F, Corradini P, Larsen TS, Rueda Dominguez A, Skarbnik A, Joergensen JM, et al. Glofitamab plus polatuzumab vedotin continues to demonstrate frequent and durable responses and has a manageable safety profile in patients with ≥2L relapsed/refractory DLBCL, including HGBCL, and in patients with prior CAR T-Cell therapy: updated results from a phase Ib/II study. Blood. 2023;142(Supplement 1):4460–4460. doi:10.1182/BLOOD-2023-174213.
   Google Scholar
• https://www.postersessiononline.eu173580348_eucongresosASH2023aula-MON_4460_ASH2023.pdf.
   Google Scholar
• Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. Immunity. 2016;44(5):973–988. doi:10.1016/j.immuni.2016.04.020.
   PubMed Web of Science ®Google Scholar
• Herter S, Sam J, Ferrara Koller C, Diggelmann S, Bommer E, Schönle A, Claus C, Bacac M, Klein C, Umana P. RG6076 (CD19-4-1BBL): CD19-targeted 4-1BB ligand combination with glofitamab as an off-the-shelf, enhanced T-Cell redirection therapy for B-Cell malignancies. Blood. 2020;136(Supplement 1):40–40. doi:10.1182/BLOOD-2020-134782.
   Google Scholar
• Sam J, Hofer T, Kuettel C, Claus C, Herter S, Georges G, Thom JT, Kunz L, Gebhardt S, Limani F, et al. RG6333 (CD19-CD28), a CD19-targeted affinity-optimized CD28 bispecific antibody, enhances and prolongs the anti-tumor activity of glofitamab (CD20-TCB) in preclinical models. Blood. 2022;140(Supplement 1):3142–3143. doi:10.1182/BLOOD-2022-159941.
   Google Scholar
• Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hösser T, et al. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci Transl Med. 2019;11(496). doi:10.1126/SCITRANSLMED.AAV5989.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Carlo-Stella C, Gritti G, Bosch F, Morschhauser F, Townsend W, Offner F, Walter HS, Ghesquieres H, Houot R, et al. CD19 4-1BBL (RO7227166) a novel costimulatory bispecific antibody can be safely combined with the T-Cell-engaging bispecific antibody glofitamab in relapsed or refractory B-Cell Non-Hodgkin Lymphoma. Blood. 2022;140(Supplement 1):9461–9463. doi:10.1182/BLOOD-2022-157011.
   Google Scholar
• Dickinson M, Gritti G, Carlo-Stella C, Walter HS, Carlile D, Getzmann N, Curdt S, Harrop E, Keelara A, Korfi K, et al. Phase 1 study of CD19 targeted CD28 costimulatory agonist in combination with glofitamab to enhance T cell effector function in relapsed/refractory B cell lymphoma. Blood. 2022;140(Supplement 1):3818–3820. doi:10.1182/BLOOD-2022-156808.
   Google Scholar
• Byun JM, Yoon S-S, Hong J, Shin D-Y, Koh Y. P1157 Phase ii study of glofitamab, poseltinib and lenalidomide in patients with relapsed/refractory diffuse b cell lymphomas. HemaSphere. 2023;7(Supplement 3): e36320c6. doi:10.1097/01.HS9.0000971524.36320.c6.
   Google Scholar
• Avivi Mazza I, Kim WS, Ko P-S, Grande C, Lavie D, Chism D, Seliem M, Jeng EE, Joshi N, Siddani S, et al. Subcutaneous epcoritamab plus lenalidomide in patients with Relapsed/Refractory diffuse large B-Cell lymphoma from EPCORE NHL-5. Blood. 2023;142(Supplement 1):438–438. doi:10.1182/BLOOD-2023-180089.
   Google Scholar
• Hou J-Z, Jacobs R, Cho S-G, Devata S, Gaballa S, Yoon DH, Stevens DA, Kim JS, Buelow B, Nair R. Interim results of the phase 1 study of tnb-486, a Novel CD19xCD3 T-Cell engager, in patients with Relapsed/Refractory (R/R) B-NHL. Blood. 2022;140(Supplement 1):1474–1475. doi:10.1182/blood-2022-166385.
   Google Scholar
• Gaballa S, Nair R, Jacobs RW, Devata S, Cho S-G, Stevens DA, Yoon DH, Shah NN, Brennan D, Law J, et al. Double Step-up Dosing (2SUD) regimen mitigates severe icans and CRS while maintaining high efficacy in subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) treated with AZD0486, a novel CD19xCD3 T-Cell engager (TCE): updated safety and efficacy data from the ongoing first-in-human (FIH) phase 1 trial. Blood. 2023;142(Supplement 1):1662–1662. doi:10.1182/BLOOD-2023-174668.
   Google Scholar
• Song Y, Li Z, Li L, Qian Z, Zhou K, Fan L, Tan P, Giri P, Li Z, Kenealy M, et al. GB261, an Fc-Function enabled and CD3 affinity De-tuned CD20/CD3 bispecific antibody, demonstrated a highly advantageous Safety/Efficacy balance in an ongoing first-in-human dose-escalation study in patients with Relapsed/Refractory Non-Hodgkin Lymphoma. Blood. 2023;142(Supplement 1):1719–1719. doi:10.1182/BLOOD-2023-188444.
   Google Scholar
• Zhang J, Zhou Z. Preclinical study of a novel tri-specific anti-CD3/CD19/CD20 T cell-engaging antibody as a potentially better treatment for NHL. Blood. 2020;136(Supplement 1):22. doi:10.1182/BLOOD-2020-140154.
   Google Scholar
• Kuchnio A, Yang D, Vloemans N, Lowenstein C, Cornelissen I, Amorim R, Han C, Sukumaran S, Janssen L, Suls T, et al. Characterization of JNJ-80948543, a novel CD79bxCD20xCD3 trispecific T-Cell redirecting antibody for the treatment of B-Cell Non-Hodgkin Lymphoma. Blood. 2022;140(Supplement 1):3105–3106. doi:10.1182/BLOOD-2022-168739.
   Google Scholar
• Lu H, Oka A, Coulson M, Polli JR, Aardalen K, Ramones M, Walker DB, Carrion A, Alexander D, Klopfenstein M, et al. PIT565, a first-in-class anti-CD19, anti-CD3, anti-CD2 trispecific antibody for the treatment of B cell malignancies. Blood. 2022;140(Supplement 1):3148–3148. doi:10.1182/BLOOD-2022-168904.
   Google Scholar
• Demaria O, Gauthier L, Vetizou M, Blanchard Alvarez A, Vagne C, Habif G, Batista L, Baron W, Belaïd N, Girard-Madoux M, et al. Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. Cell Rep Med. 2022;3(10):100783. doi:10.1016/j.xcrm.2022.100783.
   PubMedGoogle Scholar